Currently Viewing:
European Society of Cardiology (ESC) 2017
Dr Christi Deaton on the Most Important Steps for Cardiovascular Prevention
November 12, 2017
Dr John Rumsfeld: We're Just at the Beginning of the Digital Health Transformation
November 09, 2017
Dr Jeanette Stingone on Environmental Factors That Impact Public Health
November 07, 2017
Christi Deaton: Challenges of Motivating Patients to Participate in CVD Prevention Strategies
November 04, 2017
Dr John Rumsfeld on the Digital Transformation of Cardiovascular Medicine
October 24, 2017
Dr Deepak Bhatt on the Impact of the COMPASS Trial on Standard of Care
October 19, 2017
Dr Jeanette Stingone: Air Pollution Is an Issue Everywhere in the US
October 12, 2017
Dr John Rumsfeld Outlines ACC's Main Goals for the Future of Cardiology
October 07, 2017
Dr Simon Gibbs Discusses the Future of Pulmonary Hypertension Treatments
October 03, 2017
Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol
October 01, 2017
Dr John Eikelboom on the COMPASS Trial Findings
September 28, 2017
Dr John Eikelboom on the Surprising Results of the COMPASS Trial
September 15, 2017
Dr Simon Gibbs Outlines Monotherapy vs Combination Therapy in Pulmonary Hypertension
September 14, 2017
Dr Christi Deaton: Ask Cardiac Patients About Their Diet and Exercise
September 12, 2017
Dr Steven Nissen on Which Patients Should Be Treated With PCSK9 Inhibitors
September 11, 2017
Dr Jeanette Stingone on Lasting Cardiovascular Effects of Prenatal Exposure to Air Pollution
September 07, 2017
Dr Christi Deaton on Promoting Better Self-Management for Patients With CVD
August 29, 2017
Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD
August 29, 2017
Comorbidities in Patients With Heart Failure: Treating the Whole Patient
August 29, 2017
Currently Reading
Dr Simon Gibbs on Daily Management of Patients With Pulmonary Hypertension
August 28, 2017

Dr Simon Gibbs on Daily Management of Patients With Pulmonary Hypertension

Pulmonary arterial hypertension requires vigilant monitoring beyond just a superficial conversation, including several yearly tests and analyses, according to Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.


Pulmonary arterial hypertension requires vigilant monitoring beyond just a superficial conversation, including several yearly tests and analyses, according to Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.

Transcript

What are the challenges of daily management of patients with pulmonary arterial hypertension?

The most important thing with pulmonary arterial hypertension is getting the diagnosis right. And then, having made a diagnosis, they require treatment, and they require support. The treatment with the drug therapies requires very vigilant follow-up over time, as long as the patients are on treatment and the treatments are in general for life.

So, they will require follow-up every 3 to 6 months, usually at 3-monthly intervals. It’s not a matter of just sitting with a patient and saying, “Hey, how are you? Can you walk and all the rest of it? That’s fine, off you go.” It’s also critical to undertake further investigations and it’s not necessarily everything every time, but that includes blood test, 6 minute walk test, arterial blood gases or oxygen saturation, echocardiography, cardiopulmonary exercise testing, and measuring hemodynamics by right-heart catheterization.

So it’s not every visit, but at least at our institution we undertake an annual assessment once a year and do everything. If a patient changes treatment or a dose is changed, then everything is repeated after 3 or 4 months. It isn’t just a simple, “Hi, how are you getting on?” and I think that’s the important thing.

But in addition to that, the patients require support. They go to other healthcare professionals and have other medical conditions, of course, and then nobody knows whether it’s safe to do something to them or not, or to give them this drug or that drug. They all come running along, saying, can I do this, can I do that, and other doctors do the same. So there’s a lot of remote telephone support, and then there’s also seeing the patient as well.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!